A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT01153815

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01153815
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01153815. Randomized; quadruple masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2011-06 (actual). Results posted on 2012-05-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
Condition
Cerebrovascular Accident
Intervention (Drug)
GSK1358820(Botulinum toxin type A)
Intervention (Drug)
placebo
Lead sponsor
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct01153815
Content hash
2a3dc6d8908e2092db0acc96b1653458eca7fae52fdc7c41d5b823c6659830c6